Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study

Article Oncology

Genomic landscape of acquired resistance to targeted therapies in patients with solid tumors: A study from the National Center for Precision Medicine (PRISM).

Arnaud Bayle et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Letter Oncology

Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)

A. Bayle et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer

Etienne Gouton et al.

Summary: This study shows that routine cfDNA molecular profiling can guide targeted therapy selection for cancer patients, but no significant improvement in treatment outcomes was observed in this pan-cancer study.

CURRENT ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Liquid biopsy enters the clinic - implementation issues and future challenges

Michail Ignatiadis et al.

Summary: The approval of liquid biopsy assays for detecting genetic alterations in plasma cell-free DNA has marked a tipping point for the clinical use of this technology, especially in patients with advanced-stage cancer. The next frontier is likely to be the systemic treatment of patients with 'ctDNA relapse' and other potential future applications include cancer screening and diagnosis.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer

Aparna R. Parikh et al.

Summary: The study demonstrates that detection of persistent circulating tumor DNA in plasma shows favorable sensitivity and specificity for predicting recurrence after curative-intent surgery for colorectal cancer. Integrating analysis of genomic and epigenomic signatures enhances the accuracy of detection, supporting the potential clinical utility of plasma-only ctDNA minimal residual disease detection.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Review Oncology

Liquid Biopsy: From Discovery to Clinical Application

Catherine Alix-Panabieres et al.

Summary: CTC and ctDNA have been recognized as promising biomarkers with various clinical applications, including early cancer detection and therapeutic monitoring. However, challenges such as standardization and validation of clinical effectiveness need to be addressed in this dynamic field of translational cancer research.

CANCER DISCOVERY (2021)

添加到收藏夹

Review Oncology

Precision oncology: a clinical and patient perspective

Ulrik N. Lassen et al.

Summary: Precision oncology provides individualized treatment for each patient based on the unique DNA fingerprint of their cancer, with advancements in DNA sequencing technologies and decision-making tools improving therapy matching and outcomes, while increasing hope for the future. This approach has shifted cancer treatment strategies towards targeting actionable mutations found across multiple cancer types, and has proven success in improving outcomes, quality of life, and overcoming drug resistance and relapse mechanisms. Addressing challenges in its use will further improve therapy matching to patients.

FUTURE ONCOLOGY (2021)

添加到收藏夹

Article Oncology